Tivic Health Validates European Patents in Great Britain, Germany, and France
Tivic Health Systems (Nasdaq: TIVC) has validated two European Patent Office patents in Great Britain, Germany, and France. The patents cover methods for identifying treatment points and dynamically personalizing stimulation in their sinus treatment device, ClearUP. EP3615133 protects device methods for identifying treatment points and triggering treatment modes, while EP3615134 covers methods for dynamically adjusting stimulation voltage during treatment. These validations are part of Tivic's international portfolio of 16 issued and 10 pending patents across the U.S., Europe, India, and China.
Tivic Health Systems (Nasdaq: TIVC) ha convalidato due brevetti presso l'Ufficio Europeo dei Brevetti in Gran Bretagna, Germania e Francia. I brevetti riguardano metodi per identificare punti di trattamento e personalizzare dinamicamente la stimolazione nel loro dispositivo di trattamento per i seni, ClearUP. EP3615133 protegge i metodi del dispositivo per identificare i punti di trattamento e attivare le modalità di trattamento, mentre EP3615134 copre metodi per regolare dinamicamente la tensione di stimolazione durante il trattamento. Queste convalide fanno parte del portafoglio internazionale di Tivic composto da 16 brevetti rilasciati e 10 in attesa negli Stati Uniti, in Europa, in India e in Cina.
Tivic Health Systems (Nasdaq: TIVC) ha validado dos patentes de la Oficina Europea de Patentes en Gran Bretaña, Alemania y Francia. Las patentes abarcan métodos para identificar puntos de tratamiento y personalizar dinámicamente la estimulación en su dispositivo de tratamiento sinusal, ClearUP. EP3615133 protege métodos del dispositivo para identificar puntos de tratamiento y activar modos de tratamiento, mientras que EP3615134 cubre métodos para ajustar dinámicamente el voltaje de estimulación durante el tratamiento. Estas validaciones son parte del portafolio internacional de Tivic, que cuenta con 16 patentes emitidas y 10 pendientes en los Estados Unidos, Europa, India y China.
티빅 헬스 시스템즈 (Nasdaq: TIVC)는 영국, 독일, 프랑스에서 두 개의 유럽 특허청 특허를 검증했습니다. 이 특허는 그들의 부비동 치료 장치인 ClearUP에서 치료 지점을 식별하고 자극을 동적으로 개인화하는 방법을 다룹니다. EP3615133은 치료 지점을 식별하고 치료 모드를 시작하는 장치 방법을 보호하며, EP3615134는 치료 중 자극 전압을 동적으로 조정하는 방법을 포함합니다. 이러한 검증은 티빅의 미국, 유럽, 인도 및 중국에서 발행된 16개의 특허와 10개의 대기 중인 특허로 구성된 국제 포트폴리오의 일환입니다.
Tivic Health Systems (Nasdaq: TIVC) a validé deux brevets auprès de l'Office Européen des Brevets en Grande-Bretagne, en Allemagne et en France. Les brevets couvrent des méthodes pour identifier les points de traitement et personnaliser dynamiquement la stimulation dans leur dispositif de traitement du sinus, ClearUP. EP3615133 protège les méthodes du dispositif permettant d'identifier les points de traitement et de déclencher les modes de traitement, tandis qu'EP3615134 couvre des méthodes pour ajuster dynamiquement la tension de stimulation pendant le traitement. Ces validations font partie du portefeuille international de Tivic, qui comprend 16 brevets délivrés et 10 en attente aux États-Unis, en Europe, en Inde et en Chine.
Tivic Health Systems (Nasdaq: TIVC) hat zwei Patente des Europäischen Patentamtes in Großbritannien, Deutschland und Frankreich validiert. Die Patente betreffen Methoden zur Identifizierung von Behandlungsstellen und zur dynamischen Personalisierung der Stimulation in ihrem Nasenbehandlungsgerät ClearUP. EP3615133 schützt die Methoden des Geräts zur Identifizierung von Behandlungsstellen und zum Auslösen von Behandlungsmodi, während EP3615134 Methoden zum dynamischen Anpassen der Stimulationsspannung während der Behandlung umfasst. Diese Validierungen sind Teil des internationalen Portfolios von Tivic, das aus 16 erteilten Patenten und 10 anhängigen Patenten in den USA, Europa, Indien und China besteht.
- Expansion of patent protection in key European markets
- Strong intellectual property portfolio with 16 issued and 10 pending patents globally
- None.
Insights
The validation of these bioelectronic patents in key European markets has minimal immediate financial impact on Tivic Health. While patent protection is important for medical device companies, these validations are primarily defensive measures that protect existing intellectual property rather than generating new revenue streams. For a micro-cap company with
The technology protected by these patents - adaptive triggering and dynamic stimulation voltage adjustment - represents incremental improvements to their ClearUP sinus treatment device. However, without accompanying commercialization plans or revenue projections for these markets, the immediate business impact remains The expanded patent portfolio may enhance the company's attractiveness for potential partnerships or acquisitions, but investors should focus more on near-term revenue generation and market penetration metrics.
Patents cover methods used to identify key treatment points and dynamically personalize simulation
Newly validated patents in
- European Patent EP3615133, both titled “Adaptive Trigger For a Microcurrent Stimulation Device” protects device and methods that the company uses to identify preferred treatment points and trigger the treatment mode of its sinus treatment device. Triggers can be programmed in various ways to improve consumer performance and ease of use.
- European Patent EP3615134 entitled “Sinus Treatment Device With Adaptive Circuit” protects the device and methods that the company uses to dynamically adjust stimulation voltage that is applied during a treatment phase, allowing for dynamic personalization of treatment. The dynamic changes in stimulation voltage help to maximize comfort, enhance device performance, and enrich user experience.
“Validation of these key patents in
About Tivic Health
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP™ is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP™ is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the future development of ncVNS treatment, the Tivic Health’s ability to commercialize products arising out of the ncVNS treatment and the Tivic Health’s plans to seek regulatory approval for such clinical products and Tivic Health’s continued focus on developing ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and/or ischemic stroke space; expected clinical utility including which patient populations may be pursued; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health’s actual results to differ from those contained in the forward-looking statements, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112717304/en/
Media Contact:
Morgan Luke
Morgan.Luke@tivichealth.com
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Source: Tivic Health Systems, Inc.
FAQ
What patents did Tivic Health (TIVC) validate in Europe?
How many patents does Tivic Health (TIVC) currently hold?
What technology do Tivic Health's (TIVC) new European patents protect?
